History
History icon
The French Atomic Energy Commission (CEA) has been studying the impact of radiation on DNA for several decades. This research has resulted in a good understanding of the essential DNA repair mechanisms.
Recently, a set of innovative biomarkers was developed providing a complete functional signature for these mechanisms. This signature is now exploited as part of powerful tools for personalized cancer treatment.

DNA Repair meets diagnostics

LXRepair is a CEA spin-off building on over 25 years' research into the science behind DNA repair mechanisms and in vitro diagnostics for cancer.
Awards
Awards icon
Biovision Catalyser Awards winner 2013
Ministry of High Education, Reasearch and Innovation Awards Company of Innovative Technology
Team
Dr Sylvie SAUVAIGO, LXRepair CEO, CSO

Sylvie SAUVAIGO, PhD

Founder, Chief Scientific Officer
Sylvie Sauvaigo found­ed LX­Repair, a CEA’s spin-off, in 2013. She is res­pon­si­ble for LX­Repair R&D and clin­i­cal pro­grams.
She is gra­d­u­at­ed of the INSA school of En­gi­neer­ing and has a strong back­ground in chemist­ry and bio­chemist­ry. She got her PhD from Uni­ver­si­ty of Gre­no­ble.
Pas­sion­ate about in­no­va­tion and tech­no­log­i­cal break­throughs she start­ed her car­ri­er as Pro­ject Man­ag­er at Cis bio inter­na­tion­al where she de­vel­oped in­no­va­tive diag­nos­tic as­says for infec­tious dis­eases. She joined CEA where she fo­cused on DNA dam­age and DNA Re­pair. She led a group in the Tech­nolo­gies for health pro­gram to de­vel­op first-of-its-kind tech­nology for DNA Repair char­ac­ter­­i­za­tion.
Stéphane ATALBA, LXRepair CEO, PhD, ESCP

Stéphane ALTABA, ESCP, PhD

Chief Executive Officer
Stéphane Altaba, 55 year-old, holds a PhD in bio­techno­logy (INPL) and a degree from the École Supé­rieure de Com­merce de Paris (ESCP-Europe). From 1994 and for more than 12 years, Stéphane Altaba held various respon­sibi­li­ties within the Sanofi Group: from R&D to Indus­trial Affairs, then Busi­ness Develop­ment. The last posi­tion he held at Sanofi was Group Director of Onco­logy Agree­ments and Licen­sing.
During his 9 years with Nordic Pharma, he esta­bli­shed several strate­gic partner­ships with other pharma­ceu­ti­cal com­pa­nies and set up a net­work of sub­si­diaries in Europe for the marke­ting of the com­pany's main pro­ducts.
In 2015, he joined Genomic Vision a mole­cular diagnos­tics com­pany where he was a member of the board and Chief Ope­ra­ting Officer. He success­fully re­organi­zed the com­pany around the main markets of interest, in diagnos­tics, bio­produc­tion and preci­sion medi­cine, which led to a signi­fi­cant growth in sales.
François Xavier Desforges, experienced Manager of innovative start-ups companies

François-Xavier DESFORGES, PhD

Chief Financial Officer
FX Desforges is an expe­rien­ced Man­ager of High Techno­lo­gies/­In­no­va­tive start-ups com­pa­nies in va­rious mar­kets (Health, Mari­time, Ins­tru­men­ta­tion, …) with a broad expe­rience in va­rious domains (Sales & Mar­ke­ting of In­no­va­tive Pro­ducts, Fi­nance, Busi­ness Plan, HR, R&D, …). Recent­ly, he was CEO of Presto­diag SAS, a diagnos­tic com­pa­ny in food safe­ty and from 2007, he was CEO of Gene­wave SAS where he engi­neered the mer­ger with Mobi­diag in 2013. Mobi­diag was acqui­red by Hologic in 2021 for 800 M$.
François-Xavier gra­dua­ted from ENS Cachan in 1983 and earned a PhD in Elec­tro­nics from Uni­ver­si­ty of Limoges in 1989.
Dr Thierry MAILLET, LXRepair Diagnostic & QMS Manager

Thierry MAILLET, PhD

Chief Technical Officer
Thierry Maillet joined LX­Repair in Fe­brua­ry 2018 as Diagnos­­tic Deve­lop­­ment and Qua­l­i­­ty Man­a­g­er.
Thierry earned a PhD in Mole­c­u­­lar Bio­­chem­is­try and Bio­­phy­sics from the Uni­­ver­­si­­ty of Or­léans.
Thierry has over 25 years of ex­pe­­ri­ence in the in vi­tro diagnos­­tic in­dus­­try.
Af­ter 18 years at Stago as De­vel­op­­ment and Manu­­fac­­tu­ring man­a­g­er, he spent near­­ly 5 years at the French reg­u­la­­to­ry au­tho­r­i­­ty for health pro­ducts safe­­ty as a Cer­ti­­fied Inspec­tor.
Sarah LIBERT, LXRepair Lab Manager Quality, Service, Production, R&D Engineer

Sarah LIBERT

R&D Engineer, Lab Manager Quality, Service, Production
Sarah Libert joined LX­­Re­pair in 2014 as re­­search en­gi­­neer.
She has a Mas­­ter De­­gree in bio­tech­no­lo­­­gy from the Uni­­ver­­si­­ty of Science of Grenoble. She cur­­ren­t­ly holds the po­si­­tion of ser­­vice and pro­­duc­­tion man­­­ager and is ac­ti­ve­­ly in­­vol­ved in im­­ple­men­­ta­­tion of qua­li­­ty man­a­ge­­ment sys­­tem and R&D pro­­grams.
Through­­out her ca­reer, she has de­vel­o­ped skills in cell cul­­ture, mole­c­u­­lar bio­logy and bio­chips.
Prior to join LX­Repair, she spent 7 years wor­k­ing in a bio­tech­no­l­o­­gy start-up en­vi­ron­­ment at Mellitech.
Dr Giovanna MUGGIOLU, LXRepair Project Leader

Dr Giovanna MUGGIOLU

R&D Project Leader
Dr. Giovanna Muggiolu joined LX­­Repair in No­­vem­­­ber 2017 as Head of Re­­­search and Develop­­­ment. Her re­­­search fo­cus­es on de­­­fi­­ning a DNA Re­­pair enzy­­ma­­­tic sig­na­­­ture that character­­­izes the pa­­­tient’s re­s­­ponse to ra­­­dio and chemo­­­ther­a­py. Her pri­or re­­­search fo­cused on mole­­c­u­­­lar mech­a­­­nisms in­­­du­­ced by ion­i­­z­ing ra­di­a­­­tion for emer­­g­ing can­­­cer ther­a­­­pies. She re­cei­­ved her M.A. from the Uni­­­ver­­­si­­­ty of Turin in Med­i­­­cal Bio­­tech­no­­lo­­­gies and PhD from Bordeaux Uni­­­ver­­­si­­­ty in Cel­lu­­­lar Bi­o­lo­­­gy and Physio­­­patho­­­lo­­­gy.
Bertrand TREILLARD, LXRepair Quality, R&D Engineer

Bertrand TREILLARD

R&D & Quality Engineer
Bertrand Treillard joined LX­­­Re­pair in Sep­­tem­­­ber 2017 as an En­gi­­­neer in Re­­­search and De­velop­­ment and is par­tic­u­­­lar­­­ly in­­­vol­­ved in the de­vel­op­­­ment of LX­­Re­pair di­ag­nos­­­tic tests. He spe­cial­­­izes in bio­­tech­no­­l­o­­­gy and mole­­c­u­­­lar di­ag­nos­­­tics. Pri­or to join­ing LX­­­Repair, Bertrand worked on the tech­ni­­­cal de­vel­op­­­ment of an in vit­ro di­ag­nos­­­tic test at ImmunID, al­­lowing to ob­­­tain CE mark­ing for the test and CLIA cer­ti­fi­ca­­­tion for the Lab. ­
Xavier Tatin, LXRepair PhD Student

Xavier TATIN

PhD student
Xavier Tatin joined LX­­­­Re­pair in 2018 and he is cur­­­­ren­­­t­ly do­­­­ing a PhD in col­­­­la­­­b­o­­­­ra­­­­tion with a CEA lab. Gra­­­d­u­a­­­t­ed in 2017 from Agro­­­­Paris­­­­Tech he also holds a mas­­­ter’s de­­­­gree in bio­­­tech­no­­­l­o­­­­gy. His doc­­­­to­­­r­al work is focu­­­s­ed on the de­ve­­­lop­­­­ment and the val­i­­­­da­­­­tion of a new en­zy­­­­ma­­­t­ic as­­­­say for the charac­­­­teri­­­­za­­­­tion of DNA dou­­­­ble-­­­strand breaks re­­­­pair. He also worked at the Uni­­­­ver­­­­si­­­­ty of Otago in New Zea­­­land and at Nova South­­­­eastern Uni­­­­ver­­­­si­­­­ty (FL, USA).
Marta Oliva Santiago, LXRepair PhD Student

Maria Olivia SANTIAGO

PhD student
Marta Oliva Santiago, PhD student, mem­ber of our Re­search & In­no­va­tion team, joined LX­Repair in 2019. She is in­vol­ved in the Inter­na­tio­nal Train­ing Net­work ”aDDRess” (Hori­zon 2020 Marie Skłodowska-Curie Ac­tions, https://www.itn-address.gr). Marta set up rapid multi­ple­xed screen­ing me­thods for DNA re­pair inhi­bi­tors iden­ti­fi­ca­tion and charac­teri­za­tion using LX­Repair test plat­form.­
Rajat BUCHAT, LXRepair PhD student

Rajat BUCHA

PhD student
Rajat Bucha, PhD student, member of our Re­search & In­no­va­tion team, joined LX­Repair in 2019. He is in­vol­ved in the Inter­na­tio­nal Train­ing Net­work ”Health­Age” (Hori­zon 2020 Marie Skłodowska-­Curie Ac­tions, href="https://www.itn-healthage.gr). Rajat is study­ing the conse­quen­ces of aging on DNA re­pair acti­vi­ties, parti­cu­lar­ly in the con­text of p53 muta­tions, and is work­ing on the minia­tu­ri­za­tion of DNA re­pair tests.­
Sarah LIBERT, LXRepair Lab Manager Quality, Service, Production, R&D Engineer

Sarah LIBERT

R&D Engineer, Lab Manager Quality, Service, Production
Sarah Libert joined LX­­Re­pair in 2014 as re­­search en­gi­­neer.
She has a Mas­­ter De­­gree in bio­tech­no­lo­­­gy from the Uni­­ver­­si­­ty of Science of Grenoble. She cur­­ren­t­ly holds the po­si­­tion of ser­­vice and pro­­duc­­tion man­­­ager and is ac­ti­ve­­ly in­­vol­ved in im­­ple­men­­ta­­tion of qua­li­­ty man­a­ge­­ment sys­­tem and R&D pro­­grams.
Through­­out her ca­reer, she has de­vel­o­ped skills in cell cul­­ture, mole­c­u­­lar bio­logy and bio­chips.
Prior to join LX­Repair, she spent 7 years wor­k­ing in a bio­tech­no­l­o­­gy start-up en­vi­ron­­ment at Mellitech.
Dr Giovanna MUGGIOLU, LXRepair Project Leader

Dr Giovanna MUGGIOLU

R&D Project Leader
Dr. Giovanna Muggiolu joined LX­­Repair in No­­vem­­­ber 2017 as Head of Re­­­search and Develop­­­ment. Her re­­­search fo­cus­es on de­­­fi­­ning a DNA Re­­pair enzy­­ma­­­tic sig­na­­­ture that character­­­izes the pa­­­tient’s re­s­­ponse to ra­­­dio and chemo­­­ther­a­py. Her pri­or re­­­search fo­cused on mole­­c­u­­­lar mech­a­­­nisms in­­­du­­ced by ion­i­­z­ing ra­di­a­­­tion for emer­­g­ing can­­­cer ther­a­­­pies. She re­cei­­ved her M.A. from the Uni­­­ver­­­si­­­ty of Turin in Med­i­­­cal Bio­­tech­no­­lo­­­gies and PhD from Bordeaux Uni­­­ver­­­si­­­ty in Cel­lu­­­lar Bi­o­lo­­­gy and Physio­­­patho­­­lo­­­gy.
Bertrand TREILLARD, LXRepair Quality, R&D Engineer

Bertrand TREILLARD

R&D & Quality Engineer
Bertrand Treillard joined LX­­­Re­pair in Sep­­tem­­­ber 2017 as an En­gi­­­neer in Re­­­search and De­velop­­ment and is par­tic­u­­­lar­­­ly in­­­vol­­ved in the de­vel­op­­­ment of LX­­Re­pair di­ag­nos­­­tic tests. He spe­cial­­­izes in bio­­tech­no­­l­o­­­gy and mole­­c­u­­­lar di­ag­nos­­­tics. Pri­or to join­ing LX­­­Repair, Bertrand worked on the tech­ni­­­cal de­vel­op­­­ment of an in vit­ro di­ag­nos­­­tic test at ImmunID, al­­lowing to ob­­­tain CE mark­ing for the test and CLIA cer­ti­fi­ca­­­tion for the Lab. ­
Xavier Tatin, LXRepair PhD Student

Rajat BUCHA

PhD student
Rajat Bucha, PhD student, member of our Re­search & In­no­va­tion team, joined LX­Repair in 2019. He is in­vol­ved in the Inter­na­tio­nal Train­ing Net­work ”Health­Age” (Hori­zon 2020 Marie Skłodowska-­Curie Ac­tions, href="https://www.itn-healthage.gr). Rajat is study­ing the conse­quen­ces of aging on DNA re­pair acti­vi­ties, parti­cu­lar­ly in the con­text of p53 muta­tions, and is work­ing on the minia­tu­ri­za­tion of DNA re­pair tests.­
Marta Oliva Santiago, LXRepair PhD Student

Maria Olivia SANTIAGO

PhD student
Marta Oliva Santiago, PhD student, mem­ber of our Re­search & In­no­va­tion team, joined LX­Repair in 2019. She is in­vol­ved in the Inter­na­tio­nal Train­ing Net­work ”aDDRess” (Hori­zon 2020 Marie Skłodowska-Curie Ac­tions, https://www.itn-address.gr). Marta set up rapid multi­ple­xed screen­ing me­thods for DNA re­pair inhi­bi­tors iden­ti­fi­ca­tion and charac­teri­za­tion using LX­Repair test plat­form.­
Rajat BUCHAT, LXRepair PhD student

Rajat BUCHA

PhD student
Rajat Bucha, PhD student, member of our Re­search & In­no­va­tion team, joined LX­Repair in 2019. He is in­vol­ved in the Inter­na­tio­nal Train­ing Net­work ”Health­Age” (Hori­zon 2020 Marie Skłodowska-­Curie Ac­tions, href="https://www.itn-healthage.gr). Rajat is study­ing the conse­quen­ces of aging on DNA re­pair acti­vi­ties, parti­cu­lar­ly in the con­text of p53 muta­tions, and is work­ing on the minia­tu­ri­za­tion of DNA re­pair tests.­
Strategic Committee
Gwenaël HAMON, investment chief at KREAXI

Gwenaël HAMON

Investment chief at KREAXI

Gwenaël started his career in 2009 in the Inno­­­va­­­tion Capi­­­tal team of Siparex Group, before join­­­ing the Kreaxi in De­­­cem­­­ber 2012.

To date, he has financed near­­­ly thir­­­ty compa­­­nies, two of which are now lis­­­ted, and seve­­­ral of which have been sold: Docea Power (Intel), Argo­­­sim (Dassault Sys­­­tèmes), Itris Auto­­­ma­­­tion Square (Schneider Elec­­­tric)...

He is a mem­­­ber of the Invest­­­ment Commit­­­tee of SATT Link­­­sium (Grenoble).

Gwenaël is a graduate of the École Natio­­­nale Supé­­­rieure d'Arts et Mé­­­tiers and of the Spe­­­cial­­­ised Mas­­­ter in Finan­­­cial Engineer­­­ing of EM Lyon.

Celia Hart, PhD, MBA Partner at Supernova Invest

Celia HART

PhD, MBA, General Partner at Supernova Invest

Celia has more than 20 years of expe­­­rience in the chemi­­­cal and bio­­­techno­­­lo­­­gy sec­­­tor. She joined CEA Investis­­­se­­­ment (now Super­­­nova Invest) in 2005 and has since car­­­ried out the invest­­­ments in seve­­­ral compa­­­nies opera­­­ting main­­­ly in life scien­­­ces. She ser­­­ves (or has ser­­­ved) on the Boards of seve­­­ral compa­­­nies inclu­­­ding Acu­­­surgical, Algaia, Car­­­théra, Diabe­­­loop, Fermen­­­talg, Kera­­­nova, NH Thera­­­guix, Uro­­­mems and Thera­­­nexus.

Prior to that Celia main­­­ly worked for Cam­­­bridge Anti­­­body Techno­­­lo­­­gy one of the most success­­­ful UK bio­­­techno­­­lo­­­gy com­­­panies (now Medim­­­mune follow­­­ing its acqui­­­si­­­tion by Astra Zenena) holding dif­­­fe­­­rent mana­­­ging and pro­­­duct develop­­­ment posi­­­tions inclu­­­ding Head of Lead Optimi­­­za­­­tion. She was in­­­vol­­­ved in the develop­­­ment of seve­­­ral thera­­­peu­­­tic anti­­­bo­­­dies in inclu­­­ding some in col­­­la­­­bo­­­ra­­­tion with inter­­­na­­­tio­­­nal bio­­­techno­­­lo­­­gy or pharma­­­ceu­­­ti­­­cal part­­­ners.
Celia holds a degree in Chemis­­­try from the Uni­­­ver­­­si­­­ty of Geneva (Switzer­­­land), a Ph.D. from the Uni­­­ver­­­si­­­ty of Oxford (UK) and an MBA from Grenoble École de Mana­­­ge­­­ment (France).

Guy Rigaud, founder and CEO of Sofimac and Kreaxi

Guy RIGAUD

Founder and CEO succes­si­ve­ly of the ven­ture capi­tal firms Sofi­mac and Rhône-Alpes Créa­tion (Kreaxi). More than 30 years of expe­rience in seed and ven­ture capi­tal. Cur­rent­ly lea­der of a group of inves­tors in Lyon.

Member of the Super­visory Board of Kalray (Euro­next growth ALKAL) and Phere­cydes Pharma (Euro­next growth ALPHE).

Chirstian Zbylut, CEO and international top management positions in logistics, transports, supply-chain management

Christian ZBYLUT

Christian Zbylut brings 35 years of expe­rience in CEO and inter­na­tio­nal top mana­ge­ment posi­tions in the field of logis­tics, trans­porta­tion, and sup­ply-chain mana­ge­ment. In 2013, he setup an invest­ment fund focu­sing on disrup­tive indus­try start-ups.

He served as regional CEO for Gefco Group before the sale of the compa­ny to the Rus­sian Rail­ways in De­cem­ber 2012. He star­ted his ca­reer as inter­na­tio­nal di­rec­tor for Hep­pner in Ger­ma­ny before join­ing Euro­tunnel as freight di­rec­tor, and later Chep, as CEO for France. Christian Zbylut earned a Mas­ter‘s De­gree in inter­na­tio­nal busi­ness from the École Supé­rieure des Scien­ces Com­mer­cia­les in Angers.

Sophie MANUEL, cardiologist

Sophie MANUEL

Sophie Manuel is an ex­pe­ri­enced Car­di­ol­o­gist. She also works as an auri­cu­lo-ther­a­pist in can­cerol­o­gy or as an clin­i­cal and mar­ket­ing ex­pert.
Christian DELAROCHE, President of the Supervisory Board & Board Member of Tennaxia

Christian DELAROCHE

Christian is passionate about entre­pre­neur­ship and has a broad expe­rience in transfor­ma­tio­nal chan­ge of compa­nies from re­search to com­mer­cial stage. He is an active Busi­ness Angel in stu­dy­ing and review­ing in­nova­ti­ve pro­jects before invest­ment and, more impor­tant­ly, in ac­com­pa­ny­ing start­ups teams to manage their busi­ness.
He has been 15 years, Pre­si­dent of the Super­viso­ry Board and now Board Mem­ber of Ten­naxia, a compa­ny dedi­ca­ted to sus­tain­able develop­ment. He is Board mem­ber of Seekyo and Wefight, two start­ups opera­ting in the health domain.
He is mem­ber of Centrale Supélec Busi­ness Angels help­ing stu­dents to build their busi­ness plan for start­up crea­tion.
Previous­ly, for 30 years, he has occu­pied various mana­ging posi­tions in engi­neer­ing and market­ing within IBM France and IBM Europe.
Christian is a gra­duate engi­neer from the École Centrale de Paris.
Gwenaël HAMON, investment chief at KREAXI

Gwenaël HAMON

Investment chief at KREAXI

Gwenaël started his career in 2009 in the Inno­­­va­­­tion Capi­­­tal team of Siparex Group, before join­­­ing the Kreaxi in De­­­cem­­­ber 2012.

To date, he has financed near­­­ly thir­­­ty compa­­­nies, two of which are now lis­­­ted, and seve­­­ral of which have been sold: Docea Power (Intel), Argo­­­sim (Dassault Sys­­­tèmes), Itris Auto­­­ma­­­tion Square (Schneider Elec­­­tric)...

He is a mem­­­ber of the Invest­­­ment Commit­­­tee of SATT Link­­­sium (Grenoble).

Gwenaël is a graduate of the École Natio­­­nale Supé­­­rieure d'Arts et Mé­­­tiers and of the Spe­­­cial­­­ised Mas­­­ter in Finan­­­cial Engineer­­­ing of EM Lyon.

Celia Hart, PhD, MBA Partner at Supernova Invest

Celia HART

PhD, MBA, General Partner at Supernova Invest

Celia has more than 20 years of expe­­­rience in the chemi­­­cal and bio­­­techno­­­lo­­­gy sec­­­tor. She joined CEA Investis­­­se­­­ment (now Super­­­nova Invest) in 2005 and has since car­­­ried out the invest­­­ments in seve­­­ral compa­­­nies opera­­­ting main­­­ly in life scien­­­ces. She ser­­­ves (or has ser­­­ved) on the Boards of seve­­­ral compa­­­nies inclu­­­ding Acu­­­surgical, Algaia, Car­­­théra, Diabe­­­loop, Fermen­­­talg, Kera­­­nova, NH Thera­­­guix, Uro­­­mems and Thera­­­nexus.

Prior to that Celia main­­­ly worked for Cam­­­bridge Anti­­­body Techno­­­lo­­­gy one of the most success­­­ful UK bio­­­techno­­­lo­­­gy com­­­panies (now Medim­­­mune follow­­­ing its acqui­­­si­­­tion by Astra Zenena) holding dif­­­fe­­­rent mana­­­ging and pro­­­duct develop­­­ment posi­­­tions inclu­­­ding Head of Lead Optimi­­­za­­­tion. She was in­­­vol­­­ved in the develop­­­ment of seve­­­ral thera­­­peu­­­tic anti­­­bo­­­dies in inclu­­­ding some in col­­­la­­­bo­­­ra­­­tion with inter­­­na­­­tio­­­nal bio­­­techno­­­lo­­­gy or pharma­­­ceu­­­ti­­­cal part­­­ners.
Celia holds a degree in Chemis­­­try from the Uni­­­ver­­­si­­­ty of Geneva (Switzer­­­land), a Ph.D. from the Uni­­­ver­­­si­­­ty of Oxford (UK) and an MBA from Grenoble École de Mana­­­ge­­­ment (France).

Guy Rigaud, founder and CEO of Sofimac and Kreaxi

Guy RIGAUD

Founder and CEO succes­si­ve­ly of the ven­ture capi­tal firms Sofi­mac and Rhône-Alpes Créa­tion (Kreaxi). More than 30 years of expe­rience in seed and ven­ture capi­tal. Cur­rent­ly lea­der of a group of inves­tors in Lyon.

Member of the Super­visory Board of Kalray (Euro­next growth ALKAL) and Phere­cydes Pharma (Euro­next growth ALPHE).

Christian DELAROCHE, President of the Supervisory Board & Board Member of Tennaxia

Christian DELAROCHE

Christian is passionate about entre­pre­neur­ship and has a broad expe­rience in transfor­ma­tio­nal chan­ge of compa­nies from re­search to com­mer­cial stage. He is an active Busi­ness Angel in stu­dy­ing and review­ing in­nova­ti­ve pro­jects before invest­ment and, more impor­tant­ly, in ac­com­pa­ny­ing start­ups teams to manage their busi­ness.
He has been 15 years, Pre­si­dent of the Super­viso­ry Board and now Board Mem­ber of Ten­naxia, a compa­ny dedi­ca­ted to sus­tain­able develop­ment. He is Board mem­ber of Seekyo and Wefight, two start­ups opera­ting in the health domain.
He is mem­ber of Centrale Supélec Busi­ness Angels help­ing stu­dents to build their busi­ness plan for start­up crea­tion.
Previous­ly, for 30 years, he has occu­pied various mana­ging posi­tions in engi­neer­ing and market­ing within IBM France and IBM Europe.
Christian is a gra­duate engi­neer from the École Centrale de Paris.
Sophie MANUEL, cardiologist

Sophie MANUEL

Sophie Manuel is an ex­pe­ri­enced Car­di­ol­o­gist. She also works as an auri­cu­lo-ther­a­pist in can­cerol­o­gy or as an clin­i­cal and mar­ket­ing ex­pert.
Christian DELAROCHE, President of the Supervisory Board & Board Member of Tennaxia

Christian DELAROCHE

Christian is passionate about entre­pre­neur­ship and has a broad expe­rience in transfor­ma­tio­nal chan­ge of compa­nies from re­search to com­mer­cial stage. He is an active Busi­ness Angel in stu­dy­ing and review­ing in­nova­ti­ve pro­jects before invest­ment and, more impor­tant­ly, in ac­com­pa­ny­ing start­ups teams to manage their busi­ness.
He has been 15 years, Pre­si­dent of the Super­viso­ry Board and now Board Mem­ber of Ten­naxia, a compa­ny dedi­ca­ted to sus­tain­able develop­ment. He is Board mem­ber of Seekyo and Wefight, two start­ups opera­ting in the health domain.
He is mem­ber of Centrale Supélec Busi­ness Angels help­ing stu­dents to build their busi­ness plan for start­up crea­tion.
Previous­ly, for 30 years, he has occu­pied various mana­ging posi­tions in engi­neer­ing and market­ing within IBM France and IBM Europe.
Christian is a gra­duate engi­neer from the École Centrale de Paris.
Partners
bpifrance, LXRepair's partner
Preuve du concept, LXRepair's partner
CLARA, Cancérologie Lyon Auvergne Rhône-Alpes, LXRepair's partner
Medic@lps, LXRepair's partner
Institut de cancérologie de la Loire Lucien Neuwirth, LXRepair's partner
LYONBIOPOLE, LXRepair's partner
Université de Lyon, LXRepair's partner
CHU Grenoble Alpes, LXRepair's partner
Hopitaux de Lyon, LXRepair's partner
La Région Auvergne-Rhône-Alpes, LXRepair's partner
Localization
  

LXRepair SAS

BIOPOLIS
5, avenue du Grand Sablon
38700 La Tronche
FRANCE